Comparative Effectiveness of Percutaneous and Surgical Revascularisation in Ischaemic Left Ventricular Systolic Dysfunction: Combined Patient-Level Analysis of the REVIVED-BCIS2 and STICH Trials

2 September 2024 (08:48 - 09:00)

Organised by:

Video

Sign in for access options

Slides

About the speaker

Doctor Matthew Ryan

King's College London, London (United Kingdom of Great Britain & Northern Ireland)

7 More presentations in this session

Presentation thumbnail

Extracorporeal life support for acute myocardial infarction complicated by cardiogenic shock - 12 months results of the ECLS-SHOCK trial

Professor S. Desch (Leipzig, DE)

Presentation thumbnail

Impact of baseline surgical risk on the treatment effect of PCI and CABG in ischemic left ventricular systolic dysfunction: results of the REVIVED-BCIS2 and STICH randomized controlled trials

Doctor G. Marquis-Gravel (Montreal, CA)

Presentation thumbnail

Empagliflozin for prevention of acute kidney injury in patients with type 2 diabetes mellitus undergoing extracorporeal on-pump CABG: The POST-CABGDM trial

Doctor F. Pitta (Sao Paulo, BR)

Presentation thumbnail

Temporary mechanical circulatory support in infarct-related cardiogenic shock - An individual patient data meta-analysis of all randomized trials with 6-month follow-up

Professor H. Thiele (Leipzig, DE)

Presentation thumbnail

Urgent surgery compared to fibrinolytic therapy for the treatment of left-sided mechanical valve thrombosis (SAFE-PVT): a randomized controlled trial

Professor G. Karthikeyan (New Delhi, IN)

Access the full session

Session thumbnail

Smaller trials and trial updates on shock, surgery, and other interventions

The Event

Event poster

ESC Congress 2024

2 September 2024 08:48 CET

You may be interested in

Congress Presentation

Impact of baseline surgical risk on the treatment effect of PCI and CABG in ischemic left ventricular systolic dysfunction: results of the REVIVED-BCIS2 and STICH randomized controlled trials

Congress Presentation

There is a role for PCI in patients with HFrEF - pro

Congress Presentation

Revascularisation for ischaemic cardiomyopathy: surgery, percutaneous intervention, or optimal medical therapy alone?

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources